Nasopharyngeal neoplasm
Therapeutic area
Oncology
Rare disease
No
- Definition
- A benign or malignant neoplasm affecting the nasopharynx. Representative examples of benign neoplasms include angiofibroma and squamous papilloma. Representative examples of malignant neoplasms include keratinizing squamous cell carcinoma and nonkeratinizing carcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Nasopharyngeal neoplasm
- Therapeutic area
- Oncology
- nasopharyngeal neoplasm
- nasopharyngeal neoplasms
- nasopharyngeal tumor
- nasopharyngeal tumour
- nasopharynx neoplasm
- nasopharynx neoplasm (disease)
- nasopharynx tumor
- nasopharynx tumour
- neoplasm of nasopharynx
- neoplasm of the nasopharynx
- tumor of nasopharynx
- tumor of the nasopharynx
- tumour of nasopharynx
- tumour of the nasopharynx
- Severity
- Severe
- Oncology
- Pulmonology
- MONDO ID
- MONDO:0005375
- Parent condition
- MONDO:0004821
Related records
Broader conditions (16)
- Cancer or benign tumor
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disorder of pharynx
- Head and neck neoplasm
- Human disease
- Nasopharyngeal disorder
- Neoplasm
- Neoplastic disease or syndrome
- Otorhinolaryngologic disease
- Pharynx neoplasm
- Respiratory system disorder
- Respiratory tract neoplasm
- Upper respiratory tract disorder
Narrower conditions (6)
- Benign neoplasm of nasopharynx
- Carcinoma in situ of nasopharynx
- Malignant tumor of nasopharynx
- Nasopharyngeal carcinoma
- Nasopharyngeal teratoma
- Undifferentiated carcinoma of nasopharynx
Trials (225)
- 124I-FIAU Imaging in EBV and KSHV Associated Cancers
- 18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study
- 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
- 3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma
- 68Ga-FAPI-46 PET/CT for the Prediction of Clinical Response to Neoadjuvant Therapy in Nasopharyngeal Carcinoma Patients
- A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
- A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
- A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery
- A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
- A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
- A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
- A Pilot Study of Acupuncture Treatment for Dysphagia
- A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
- A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
- A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors
- A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
- A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer
- A Study of Nasopharyngeal Carcinoma From Guangdong
Approved drugs (1)
- Sotagliflozin
Drugs in development (49)
- Avelumab Phase 2
- Axitinib Phase 2
- Azacitidine Phase 2
- Becotatug vedotin Phase 2
- Bevacizumab Phase 2
- Cadonilimab Phase 2
- Camrelizumab Phase 3
- Capecitabine Phase 3
- Carboplatin Phase 2
- Catequentinib Phase 2
- Cisplatin Phase 3
- Cyanocobalamin Phase 2
- Cyclophosphamide Phase 1
- Docetaxel Phase 3
- Doxorubicin Phase 2
- Endostatin Phase 2
- Endostatin, N-terminal-mggshhhhh Phase 2
- Envafolimab Phase 2
- Erlotinib Phase 2
- Everolimus Phase 1